前瞻性研究巨细胞病毒血清状态与前列腺癌预防试验中的前列腺癌风险。
Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial.
机构信息
Division of Public Health Sciences and the Alvin J. Siteman Cancer Center, Department of Surgery, Washington University School of Medicine, 660 S. Euclid Ave., Rm. 5026, Box 8100, St. Louis, MO 63110, USA.
出版信息
Cancer Causes Control. 2012 Sep;23(9):1511-8. doi: 10.1007/s10552-012-0028-5. Epub 2012 Jul 19.
PURPOSE
To investigate serologic evidence of infection by cytomegalovirus (CMV), a herpesvirus with known oncogenic potential that has been detected in malignant prostate tissue, in relation to prostate cancer (PCa) risk in a large case-control study nested in the Prostate Cancer Prevention Trial (PCPT).
METHODS
Cases were men with a confirmed diagnosis of PCa after visit 2 (n = 614), and controls were men not diagnosed with PCa during the trial who also had a negative end-of-study biopsy (n = 616). Controls were frequency-matched to cases by age, treatment arm, and family history of PCa. Sera from visit 2 were tested for CMV IgG antibodies.
RESULTS
No association was observed between CMV serostatus and PCa risk (adjusted CMV seroprevalence = 67.9 % for cases and 65.2 % for controls, odds ratio = 1.13, 95 % CI 0.89-1.45).
CONCLUSIONS
Considering our null findings in the context of the full CMV literature, CMV infection, as measured by serostatus, does not appear to increase PCa risk.
目的
在前列腺癌预防试验（PCPT）中进行的一项大型病例对照研究中，调查巨细胞病毒（CMV）感染的血清学证据与前列腺癌（PCa）风险的关系。CMV 是一种具有已知致癌潜力的疱疹病毒，已在恶性前列腺组织中检测到。
方法
病例为在第 2 次访视后确诊为 PCa 的男性（n=614），对照组为在试验期间未被诊断为 PCa 且研究结束时活检结果为阴性的男性（n=616）。对照组通过年龄、治疗臂和 PCa 家族史与病例进行频率匹配。第 2 次访视时的血清检测 CMV IgG 抗体。
结果
CMV 血清阳性状态与 PCa 风险之间未观察到关联（病例的 CMV 血清流行率为 67.9%，对照组为 65.2%，比值比=1.13，95%置信区间为 0.89-1.45）。
结论
考虑到我们在完整的 CMV 文献中的阴性发现，CMV 感染（通过血清阳性状态衡量）似乎不会增加 PCa 风险。
Zotero 插件